clinical trial · NCT06940154
Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)
Connect Biopharm LLC·phase2·completed·n = 159
COPD Acute ExacerbationRademikibart in prefilled syringeMatching placebo in prefilled syringe
brief summary
This is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation
started
Aug 12, 2025
primary completion
Jul 30, 2026
completion
Aug 26, 2026
last updated
Sep 16, 2026
detailed description
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, interventional trial in participants with an acute COPD exacerbation with type 2 inflammation in the urgent healthcare setting to compare rademikibart plus standard therapy to standard therapy (plus placebo).
official title
A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Rademikibart as an Add-on Treatment for Acute Exacerbation in Participants With Chronic Obstructive Pulmonary Disease and Type 2 Inflammation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol